Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof

Inventors

Han, Sangdon • Kim, Sun Hee • ZHU, Yunfei

Assignees

Crinetics Pharmaceuticals Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12479825-B2

Patent

Publication Date

2025-11-25

Expiration Date


Abstract

Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.

Core Innovation

The patent claims compounds of Formula (I), subseries thereof, and related scaffold families as melanocortin receptor modulators, particularly MC2R antagonists, or pharmaceutically acceptable salts or solvates thereof. Formula (I) defines alternatives for substituents, aromatic groups, linkers, and ring systems, wherein at least one of L and M is —O—. The disclosed compounds include substituted bipyridines containing piperazine or piperidine groups with varied aromatic, heterocyclic, heteroaryl, amine, amide, sulfonamide, sulfanyl, and sulfonyl variants.

The description encompasses stereoisomers, isotopically labeled compounds, prodrugs, active metabolites, and specifically enumerated compounds, reporting hMC2R binding potency where most tested compounds show a Ki below 100 nM. An independent claim recites a specifically listed set of substituted bipyridine and related compounds for reducing adrenocorticotropic hormone secretion and treating conditions such as Cushing's syndrome. Because introductory sections are omitted, the problem being solved is not explicitly described in patent.

Claims Coverage

The provided claim information identifies two independent claims encompassing two inventive features.

Formula (I) compound genus

Independent claim 1 covers a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, defining alternatives for substituents, aromatic groups, linkers, and ring atoms, with the proviso that at least one of L and M is —O—.

Specifically enumerated compounds

A separate independent claim covers a specified list of substituted bipyridine and related compounds containing piperazine or piperidine moieties with varied aromatic, heterocyclic, amine, amide, sulfonamide, sulfanyl, or sulfonyl substituents, or a pharmaceutically acceptable salt or solvate thereof.

The independent claims cover both a broad Formula (I) genus and an extensive list of specifically recited compounds, supported by dependent claims for pharmaceutical compositions, reduction of ACTH secretion, and treatment of specified diseases.

Stated Advantages

Not explicitly described in patent.

Documented Applications

Pharmaceutical compositions comprising a claimed compound, pharmaceutically acceptable salt, or solvate, and at least one pharmaceutically acceptable excipient.

Treatment of Cushing’s syndrome, ectopic Cushing’s syndrome, ectopic ACTH syndrome, or congenital adrenal hyperplasia (CAH) in a mammal by administering a claimed compound, pharmaceutically acceptable salt, or solvate.

Reduction of adrenocorticotropic hormone (ACTH) secretion in a mammal by administering a claimed compound, pharmaceutically acceptable salt, or solvate.

Modulating MC2R, including the use of the compounds as MC2R antagonists.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.